Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
This is a continuation application claiming priority to application U.S. Ser. No. 09/234,182 filed 20 Jan. 1999 now abandoned, provisional application U.S. Ser. No. 60/074,330 filed 22 Jan. 1998, provisional application U.S. Ser. No. 60/094,013 filed 24 Jul. 1998, provisional application U.S. Ser. No. 60/094,003 filed 24 Jul. 1998, and provisional application U.S. Ser. No. 60/075,467 filed 20 Feb. 1998, the entire disclosures of which applications are incorporated herein by reference.
